Leadership Team
Meet the visionary leaders driving quantum innovation in healthcare
Dr. Gustavo H. Olivera, Ph.D., MBA, FACHE, CPHQ, CGBLSS
Chief Executive Officer and Co-Founder at Quantum Theranostics
Dr. Gustavo H. Olivera is a healthcare innovator, physicist, and entrepreneur with over 30 years of experience pioneering cancer technology commercialization and global healthcare delivery. He is one of the original developers of TomoTherapy, where he co-led the platform's development, FDA approval, and NASDAQ IPO, establishing it as one of the most significant radiation oncology innovations of its generation. He also co-developed Adaptivo, an adaptive radiotherapy system that transformed clinical workflows.
Dr. Olivera later managed global technology and operations at 21st Century Oncology, overseeing 300+ clinics at billion-dollar scale, integrating advanced regulated clinical products into frontline cancer care. His contributions span 250+ peer-reviewed publications, 100+ issued patents, and multiple translational technologies that bridged quantum physics, imaging, and precision oncology.
Google Scholar Metrics:
- • Citations: 13,793 (total); 3,047 (since 2020)
- • h-index: 63 (total); 34 (since 2020)
- • i10-index: 117 (total); 62 (since 2020)
He holds a Ph.D. in Physics, an MBA, and advanced healthcare leadership credentials including FACHE (Fellow of the American College of Healthcare Executives), CPHQ (Certified Professional in Healthcare Quality), and CGBLSS (Certified Green Belt Lean Six Sigma). These qualifications position him at the intersection of deep science, healthcare operations, regulatory strategy, and business leadership.
Role in Quantum Theranostics (QTX):
As CEO & Co-Founder, Dr. Olivera leads the company's strategic vision, commercialization roadmap, and clinical translation strategy. He directs AI & Image Reconstruction and Prototype Engineering and co-leads Clinical Translation. He is responsible for regulatory engagement, investor relations, and strategic partnerships, ensuring that QTX's breakthrough quantum medicine platform evolves as both a scientific pioneer and a globally scalable healthcare enterprise.
Areas of Expertise:
- Quantum imaging & spectroscopy
- Adaptive radiotherapy & oncology innovation
- AI and quantum computing integration in healthcare
- Global healthcare operations & commercialization
- Regulatory strategy & quality management
- Strategic partnerships and translational medicine
Saiful Huq, PhD, FAAPM, FInstP
Chief Scientific Officer and Co-Founder at Quantum Theranostics
Dr. M. Saiful Huq is a global leader in medical physics and oncology innovation with over three decades of experience advancing clinical physics, radiotherapy quality, and international cancer care.. He is Professor of Radiation Oncology at the University of Pittsburgh School of Medicine and directs radiation oncology physics operations across 24 UPMC Hillman Cancer Centers, one of the largest networks in the United States. He has authored 185+ peer-reviewed publications, delivered 240+ invited talks globally, and served as President and Chair of the Board of the American Association of Physicists in Medicine (AAPM). His leadership has been recognized with the 2024 U.S. President’s Lifetime Achievement Award and the 2023 William D. Coolidge Gold Medal, AAPM’s highest honor.
Role in Quantum Theranostics (QTX):Monte Carlo modeling of nanoparticle-radiation interactions, development of novel nanoscale delivery agents, and integration of nanotechnology with entanglement-driven detection. At QTX, he is responsible for the design, development, and feasibility assessment of all system hardware, ensuring seamless translation of QTX inventions into clinical-grade devices.
Areas of Expertise:
- Radiation oncology physics & dosimetry
- Global radiotherapy quality & safety standards
- Clinical system design & Quality Assurance
- International training, mentorship, and capacity building
Stephen Avery PhD, FAAPM
Chief Visionary & Global Strategy Officer and Co-Founder at Quantum Theranostics
Dr. Stephen Avery is the Co-Founder and Chief Visionary & Global Strategy Officer of QTX Biosystems. He brings over two decades of leadership in radiation oncology physics, translational research, and international technology deployment, with a strong track record of fostering multidisciplinary partnerships to advance innovative cancer care solutions. He currently serves as Professor of Radiation Oncology and Director of Global Radiation Physics at the University of Pennsylvania, where he has led large-scale initiatives in radiotherapy systems, proton therapy, and global oncology collaboration. His leadership spans academic innovation, technical program development, and deep engagement with hospitals, governments, and global organizations. Dr. Avery has received the United States President’s Lifetime Achievement Award in recognition of his contributions to science, service, and community advancement..
Role in Quantum Theranostics (QTX): As Chief Visionary & Global Strategy Officer, Dr. Avery defines the strategic direction for the development and international rollout of QTX’s quantum medicine platform. He ensures that scientific innovation is aligned with clinical priorities and operational realities, guiding the adaptation of QTX technologies for real-world healthcare environments. His work centers on building institutional and technical partnerships essential for effective implementation across a range of clinical settings..
Areas of Expertise:
- Radiation Oncology Physics
- Global Radiotherapy Quality Assurance
- Proton Therapy
- International Training and Capacity Building
- Community-Driven Health Partnerships and Global Implementation
Bashkim Ziberi, PhD
Chief Technology Officer and Co-Founder at Quantum Theranostics
Bashkim Ziberi is a nanoparticle engineering, quantum system design, and translational medical technology. With a strong background in both applied physics and biomedical engineering, he leads QTX's technical architecture, nanoscale modeling, and risk management frameworks.
Mr. Ziberi's expertise includes materials engineering, nanoparticle-radiation interactions, development of novel nanoscale delivery agents, and integration of nanotechnology with entanglement-driven detection. At QTX, he is responsible for the design, development, and feasibility assessment of all system hardware, ensuring seamless translation of QTX inventions into clinical-grade devices.
His leadership focuses on bridging deep-tech physics and engineering with clinical implementation, positioning , QTX as the first platform to harness nanoparticles not only for therapy enhancement but also as quantum photon sources inside living systems..
Areas of Expertise:
- Theranostics
- Nanoparticle engineering
- Nanoparticle functionalisation
- Diagnostics & Imaging
- System architecture
- Translational physics
- Medical device development
Ruth Beassem
Chief of Staff and Co-Founder at Quantum Theranostics
Ruth Beassem is an experienced executive specializing in strategic coordination, internal operations, and organizational leadership for complex, multidisciplinary teams. She holds a Masters in Cross Cultural and Sustainable Business Management. At QTX, she serves as Chief of Staff, where she manages executive synchronization, team cadence, and strategic project tracking.
She is responsible for ensuring cross-disciplinary communication, aligning technical, clinical, and business objectives, and coordinating the company's board and advisory logistics. With a background in healthcare operations and organizational management, Ms. Beassem plays a critical role in enabling QTX's global operations to function cohesively and efficiently.
Her leadership extends to supporting the strategic execution of QTX's roadmap, helping to align the company's scientific vision with practical deliverables and ensuring that all stakeholders from clinical partners to investors remain fully engaged and informed.
Areas of Expertise:
- Executive operations
- Strategic alignment
- Corporate communications
- Governance support
- Organizational leadership